ANI Pharma (ANIP) Misses Q2 EPS by 21c, Updates Guidance

ANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $1.13, $0.21 worse than the analyst estimate of $1.34. Revenue for the quarter came in at $47.3 million versus the consensus estimate of $51.42 million.

GUIDANCE:

ANI Pharma sees FY2018 EPS of $4.80-$5.27, versus the consensus of $5.74. ANI Pharma sees FY2018 revenue of $195-205 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• AeroVironment restates quarterly financials, citing $89M goodwill error
• Creatd files Form S-1 and reports Q1 2026 financial results